celecoxib has been researched along with chitosan in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chuttani, K; Mishra, AK; Murthy, RS; Sharma, RK; Thakkar, H | 2 |
| Gati, I; Haupt, S; Kleinstern, J; Rubinstein, A; Zioni, T | 1 |
| Chan, KW; Cheng, GY; Cheng, SY; Chui, CH; Gambari, R; Kok, SH; Lai, PB; Lam, KH; Lam, PL; Lau, FY; Tong, SW; Wong, RS; Yuen, MC | 1 |
| Azab, B; Dash, R; Fisher, PB; Kundu, SC; Mandal, M; Pathak, A; Prashanth Kumar, BN; Puvvada, N; Sarkar, D; Venkatesan, P | 1 |
| Cirri, M; Furlanetto, S; Mennini, N; Mura, P | 1 |
| Cid, YP; de Sousa, VP; Pedrazzi, V; Pierre, MB | 1 |
| Bragagni, M; Di Cesare Mannelli, L; Furlanetto, S; Ghelardini, C; Mennini, N; Mura, P | 1 |
| Cutrignelli, A; Denora, N; Depalo, N; Fanizza, E; Franco, M; Iacobazzi, RM; Laquintana, V; Lopalco, A; Lopedota, A; Mastrodonato, M; Mentino, D; Perrone, M | 1 |
| Saber-Samandari, S | 1 |
| Choi, JH; Choi, YJ; Jeong, MS; Kim, MW; Kwon, SH; Lee, R; Motoyama, K; Park, YI | 1 |
| Hadjmohammadi, MR; Majidi, SM | 1 |
| Ebrahimi, HA; Esmaeli, S; Khezri, S; Salimi, A | 1 |
| Abd El-Ghany, NA; Abdel-Aziz, MM; Elmehbad, NY; Mohamed, NA | 1 |
14 other study(ies) available for celecoxib and chitosan
| Article | Year |
|---|---|
Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints.
Topics: Animals; Arthritis, Experimental; Celecoxib; Chitosan; Delayed-Action Preparations; Drug Delivery Systems; Injections, Intra-Articular; Male; Microspheres; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2004 |
Celecoxib incorporated chitosan microspheres: in vitro and in vivo evaluation.
Topics: Animals; Celecoxib; Chitosan; Drug Evaluation, Preclinical; Male; Microspheres; Particle Size; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2004 |
Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer.
Topics: Adhesiveness; Animals; Celecoxib; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Delayed-Action Preparations; Drug Carriers; Feces; Galactans; HT29 Cells; Humans; Inhibitory Concentration 50; Intestinal Mucosa; Intestines; Male; Mannans; Particle Size; Plant Gums; Pyrazoles; Rats; Rats, Sprague-Dawley; Solubility; Sulfonamides | 2006 |
Synthesis, characterization and preliminary analysis of in vivo biological activity of chitosan/celecoxib microcapsules.
Topics: Celecoxib; Chitosan; Cyclooxygenase 2 Inhibitors; Gas Chromatography-Mass Spectrometry; Microscopy, Electron, Scanning; Microspheres; Pyrazoles; Sulfonamides | 2010 |
The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Cycle; Cell Proliferation; Chitosan; Colonic Neoplasms; Cytoskeleton; Durapatite; HT29 Cells; Humans; Mice; Mice, Nude; Nanocomposites; Pyrazoles; Sulfonamides | 2011 |
Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-β-cyclodextrin-PVP complex.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Alginates; beta-Cyclodextrins; Calcium; Celecoxib; Chemistry, Pharmaceutical; Chitosan; Colon; Drug Delivery Systems; Glucuronic Acid; Hexuronic Acids; Microspheres; Particle Size; Polymers; Povidone; Pyrazoles; Solubility; Sulfonamides | 2012 |
In vitro characterization of chitosan gels for buccal delivery of celecoxib: influence of a penetration enhancer.
Topics: Administration, Buccal; Animals; Celecoxib; Chitosan; Drug Delivery Systems; Gels; Mouth Mucosa; Permeability; Pyrazoles; Sulfonamides; Swine | 2012 |
Development of a chitosan-derivative micellar formulation to improve celecoxib solubility and bioavailability.
Topics: Animals; Biological Availability; Celecoxib; Chitosan; Cyclooxygenase 2 Inhibitors; Drug Carriers; Drug Liberation; Maximum Tolerated Dose; Mice; Micelles; Particle Size; Pyrazoles; Quaternary Ammonium Compounds; Sulfonamides; Technology, Pharmaceutical | 2014 |
Spray Dried Chitosan Microparticles for Intravesical Delivery of Celecoxib: Preparation and Characterization.
Topics: Administration, Intravesical; Animals; beta-Cyclodextrins; Celecoxib; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Freeze Drying; Microspheres; Mucous Membrane; Particle Size; Solubility; Swine; Urinary Bladder; Viscosity | 2016 |
Biocompatible nanocomposite scaffolds based on copolymer-grafted chitosan for bone tissue engineering with drug delivery capability.
Topics: Bone and Bones; Celecoxib; Chitosan; Drug Delivery Systems; Durapatite; Nanocomposites; Polymers; Tissue Engineering; Tissue Scaffolds | 2017 |
Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer.
Topics: A549 Cells; Animals; Biological Transport; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chitosan; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Lung Neoplasms; Mice; Nanoparticles; Xenograft Model Antitumor Assays | 2020 |
Dimethyldioctadecylanimonium bentonite immobilized magnetic chitosan nanoparticles as an efficient adsorbent for vortex-assisted magnetic dispersive micro-solid-phase extraction of celecoxib from human breast milk, plasma and urine samples.
Topics: Adsorption; Adult; Bentonite; Celecoxib; Chitosan; Chromatography, High Pressure Liquid; Female; Humans; Limit of Detection; Linear Models; Magnetite Nanoparticles; Milk, Human; Quaternary Ammonium Compounds; Reproducibility of Results; Solid Phase Extraction | 2020 |
Curcumin-Loaded Chitosan Nanoparticle Preparation and Its Protective Effect on Celecoxib-induced Toxicity in Rat isolated Cardiomyocytes and Mitochondria.
Topics: Animals; Antioxidants; Celecoxib; Chitosan; Curcumin; Drug Carriers; Mitochondria; Myocytes, Cardiac; Nanoparticles; Particle Size; Rats | 2023 |
Evaluation of the in vitro anti-inflammatory and anti-Helicobacter pylori activities of chitosan-based biomaterials modified with copper oxide nanoparticles.
Topics: 4-Aminobenzoic Acid; Anti-Bacterial Agents; Anti-Inflammatory Agents; Biocompatible Materials; Celecoxib; Chitosan; Copper; Cyclooxygenase 2; Helicobacter pylori; Humans; Metal Nanoparticles; Nanoparticles; Oxides | 2023 |